Related Experiment Video
Updated: Apr 12, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
1.5K
Dramatic response to selective internal radiation therapy for unresectable hepatocellular carcinoma
Woo Daniel Park1, Bob T Li2, Richard Maher3
1Department of Medical Oncology , Royal North Shore Hospital, St Leonards , Sydney, NSW , Australia.
Oxford Medical Case Reports
|May 20, 2015
Summary
Selective internal radiation therapy (SIRT) with yttrium-90 microspheres showed significant effectiveness in treating multifocal hepatocellular carcinoma, even after other treatments failed. This case highlights SIRT
Area of Science:
- Hepatobiliary oncology
- Interventional radiology
- Nuclear medicine
Background:
- Hepatocellular carcinoma (HCC) is a primary liver cancer with limited treatment options after disease relapse.
- Multifocal HCC presents a therapeutic challenge, often requiring multimodal approaches.
- Previous treatments like surgical resection and transarterial chemoembolization (TACE) had failed in this patient.
Purpose of the Study:
- To report a case of multifocal hepatocellular carcinoma treated with selective internal radiation therapy (SIRT).
- To illustrate the potential efficacy of SIRT in managing advanced HCC.
- To visually demonstrate treatment response following SIRT.
Main Methods:
- Selective internal radiation therapy (SIRT) was administered using yttrium-90 ((90)Y) labeled microspheres.
- Treatment was delivered to a 54-year-old female patient with a history of multifocal HCC.
- Disease status was monitored clinically, radiologically, and metabolically.
Main Results:
- The patient achieved a dramatic clinical, radiological, and metabolic response 9 weeks post-SIRT.
- Significant tumor burden reduction and improvement in disease markers were observed.
- SIRT demonstrated a positive impact on disease control.
Conclusions:
- Selective internal radiation therapy (SIRT) can be an effective treatment option for multifocal hepatocellular carcinoma.
- SIRT offers a potential therapeutic role in cases of HCC recurrence after conventional therapies.
- This case underscores the value of SIRT in managing challenging HCC presentations.
